Pd-1 Inhibitor Plus Chemotherapy in Relapsed/Refractory Primary Mediastinal Large B-Cell Lymphoma (Pmlbcl) With Aggressive Bulky Disease

Hematological Oncology - United Kingdom
doi 10.1002/hon.78_2630
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Wiley

Related search

Primary Mediastinal Large B-Cell Lymphoma

Oncologist
Cancer ResearchMedicineOncology
2006English

PROGNOSTIC FACTORS (PFs) IN PRIMARY MEDIASTINAL LARGE B-Cell LYMPHOMA (PMLBCL) TREATED WITH RITUXIMAB-CHOP (RCHOP) ± RADIOTHERAPY (RT)

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2019English

Primary Mediastinal Large B-Cell Lymphoma During Pregnancy

Case Reports in Hematology
2012English

Primary Mediastinal Large B-Cell Lymphoma-The Role of Mediastinal Radiation

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2017English

Rituximab, Bendamustine and Cytarabine (R-Bac) in Patients With Relapsed-Refractory Aggressive B-Cell Lymphoma

American Journal of Hematology
Hematology
2018English

Phase 1b Study of Pembrolizumab in Patients With Relapsed/Refractory Primary Mediastinal Large B-Cell Lymphoma (Rrpmbcl): Updated Results From the Keynote-013 Trial

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2017English

PD-1 Blockade With Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma

New England Journal of Medicine
Medicine
2015English

Extranodal Diffuse Large B-Cell Lymphoma With Monoclonal Gammopathy: An Aggressive and Primary Refractory Disease Responding to an Immunomodulatory Agent

Experimental Hematology and Oncology
Cancer ResearchOncologyHematology
2015English

The Dial Study (Dual Immunomodulation in Aggressive Lymphoma): Randomized Phase 2 Trial of Varlilumab Plus Nivolumab in Relapsed/Refractory Aggressive B-Cell Lymphomas

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2026 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy